錦欣生殖(01951.HK)收購康芝藥業兩家醫院權益
錦欣生殖(01951.HK)公佈,附屬四川錦欣生殖於6月18日與康芝藥業(300086.SZ)旗下廣東元寧製藥訂立股權轉讓協議,四川錦欣生殖將以3,774萬元人民幣向康芝醫院公司的10%股權。康芝醫院公司目前於雲南九洲醫院及昆明和萬家婦產醫院分別持有51%股權。
同時,公司持股15%的濱海遠賢,將以向康芝藥業的全資附屬公司及若幹獨立第三方收購康芝醫院公司的90%股權,以及持有九洲醫院及和萬家醫院的49%股權的廣州雲芝彩及廣州和家全部股權。
交易完成後,公司與濱海遠賢將分別持有康芝醫院公司10%及90%,由濱海遠賢控制上述醫院,而公司將間接享有該等醫院約19.33%的經濟利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.